Chantal Stockem

In January 2021, I joined the van der Heijden group as an MD-PhD student. I study the optimal use of systemic therapy to improve long-term outcome in locoregionally advanced and metastatic urothelial cancer.

I am involved in clinical trials with immune checkpoint inhibitors in patients with locoregionally advanced urothelial cancer, as well as translational work to gain more insight in changes by immune checkpoint inhibitors in the urothelial tumor microenvironment.